In the throes of the global pandemic that has seized the world since late 2019, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged as a formidable pathogen, responsible for causing Coronavirus Disease 2019 (COVID-19). Classified within the Betacoronavirus genus of the Coronaviridae family, SARS-CoV-2 is a positive-sense, single-stranded RNA virus, encapsulated by a distinct envelope, and shares a close genetic lineage with its predecessors, SARS-CoV-1 and the Middle East respiratory syndrome coronavirus (MERS-CoV).
Characterized by a genome approximately 30,000 base pairs in length, the virus encodes for 16 nonstructural and 4 structural proteins, crucial for its replication and infectivity. Among these, the spike (S) protein stands out for its pivotal role in the virus’s life cycle, facilitating attachment, fusion, and entry into host cells, primarily through its interaction with the angiotensin-converting enzyme-2 (ACE2) receptor and the assistance of host transmembrane proteases like TMPRSS2.
The specificity of SARS-CoV-2’s interaction with ACE2 and TMPRSS2, coupled with the differential expression of these proteins across various tissues, underscores a complex mechanism of viral entry that extends beyond the respiratory system, implicating multiple organs, including the liver, in the pathological landscape of COVID-19. Despite the respiratory system bearing the brunt of the disease, emerging evidence has illuminated the multifaceted impact of SARS-CoV-2, revealing its propensity to inflict damage on extrapulmonary organs, among which the liver has emerged as a significant site of viral replication and injury.
Research into the hepatotropic nature of SARS-CoV-2 has unveiled alarming insights into the mechanisms of liver damage associated with COVID-19. Notably, investigations have identified the presence of viral RNA within hepatocytes and endothelial cells of the liver, hinting at the direct cytopathic effects of the virus on liver tissue. These findings are supported by electron microscopic assessments and in situ hybridization analyses, which have confirmed the presence of SARS-CoV-2 particles within liver cells, alongside indications of cellular injury such as mitochondrial swelling and apoptosis.
The etiology of liver damage in COVID-19 patients is multifactorial, encompassing direct viral effects, immune-mediated damage, and consequences of systemic inflammation. Elevations in liver biochemical markers, predominantly presenting a hepatocellular pattern, have been observed in a significant proportion of COVID-19 patients, particularly those hospitalized. While the extent of these elevations varies, they highlight the liver’s vulnerability to SARS-CoV-2 infection. Furthermore, studies have suggested a link between COVID-19 and exacerbated liver conditions in individuals with pre-existing liver diseases, underscoring the need for a deeper understanding of the virus’s impact on liver health.
Exploring the molecular mechanisms underlying SARS-CoV-2 hepatotropism has revealed critical insights into the interaction between the virus and hepatic cells. The expression of ACE2 and TMPRSS2 within the liver, although comparatively lower than in other tissues like the intestine and lungs, plays a crucial role in mediating viral entry into hepatic cells.
This interaction is further complicated by the presence of additional host co-factors and the discovery of ACE2-independent pathways facilitating viral entry into liver cells. Experimental models, including hepatocellular carcinoma cell lines and organoid cultures, have proven instrumental in elucidating these mechanisms, demonstrating the liver’s permissiveness to SARS-CoV-2 infection.
The implications of SARS-CoV-2’s hepatotropism extend beyond direct viral injury, affecting various aspects of liver function and potentially contributing to long-term liver disease. The virus’s interaction with bile duct epithelial cells, or cholangiocytes, and the potential susceptibility of hepatic immune cells like Kupffer cells and hepatic stellate cells to infection, suggest a broad spectrum of liver involvement in COVID-19. These interactions may lead to alterations in bile acid metabolism, immune responses, and fibrosis, further complicating the disease’s impact on liver health.
….Let’s try to understand what’s going on….
The implications of SARS-CoV-2’s hepatotropism—its affinity for liver tissue—present a multifaceted challenge to understanding and managing COVID-19, especially in light of its potential contributions to both acute and chronic liver disease. This hepatotropism not only underscores the virus’s ability to directly infect and damage liver cells but also highlights the broader systemic effects that can impact liver function and potentially instigate or exacerbate long-term liver conditions.
Direct Viral Injury to Liver Cells
SARS-CoV-2 can directly infect liver cells, including hepatocytes and cholangiocytes, leading to cellular damage through mechanisms such as cytopathic effects, mitochondrial dysfunction, and induction of apoptosis. The presence of viral RNA and proteins within liver cells, as demonstrated in several studies, provides concrete evidence of this direct infection pathway. This direct viral injury can result in elevated liver enzymes and other biochemical markers of liver damage, reflecting hepatocyte injury.
Impact on Liver Function
Beyond direct cytopathic effects, the infection can disrupt various liver functions. The liver plays a crucial role in metabolism, detoxification, and synthesis of critical proteins. SARS-CoV-2 infection can impair these functions by causing:
- Disruption in Bile Acid Metabolism: The liver produces bile acids necessary for digestion and absorption of fats. Infection of cholangiocytes, which regulate bile acid transport and secretion, can lead to cholestasis, a condition characterized by impaired bile flow and accumulation of bile acids in the liver, potentially causing further liver damage.
- Alterations in Drug Metabolism: The liver metabolizes many medications. COVID-19 related liver dysfunction can alter drug metabolism, leading to increased toxicity or decreased efficacy of drugs, complicating the treatment of COVID-19 patients, especially those on medications for pre-existing conditions.
- Impairment of Synthetic Functions: The liver synthesizes essential proteins, including clotting factors and albumin. Viral damage can impair these functions, leading to coagulation disorders and hypoalbuminemia, complicating the clinical management of COVID-19 patients.
Indirect Effects and Systemic Inflammation
The systemic inflammatory response to SARS-CoV-2 infection can exacerbate liver damage through indirect mechanisms:
- Immune-mediated Liver Injury: The intense immune response, or cytokine storm, associated with severe COVID-19 can lead to widespread tissue damage, including in the liver. This hyperinflammatory response can exacerbate liver injury in patients with pre-existing liver diseases and even in those with previously healthy livers.
- Oxidative Stress: The systemic inflammation associated with COVID-19 increases oxidative stress, which can further damage liver cells, leading to oxidative stress-induced hepatocyte death and fibrosis.
Long-term Implications for Liver Disease
The long-term implications of COVID-19 on liver health are a growing concern. Patients recovering from COVID-19 may face increased risks of developing chronic liver diseases, such as:
- Fibrosis and Cirrhosis: The ongoing inflammation and repair processes in the liver post-SARS-CoV-2 infection may accelerate fibrosis, potentially leading to cirrhosis, especially in individuals with pre-existing liver conditions or those who develop severe COVID-19.
- Chronic Liver Disease Exacerbation: For patients with pre-existing liver diseases, such as non-alcoholic fatty liver disease (NAFLD) or hepatitis, COVID-19 may serve as a catalyst that exacerbates the progression of their liver disease.
Conclusion
The hepatotropic nature of SARS-CoV-2 has profound implications for liver function and health, extending beyond acute infection to potentially contribute to long-term liver disease. Understanding these mechanisms is crucial for developing targeted therapeutic strategies to mitigate liver damage in COVID-19 patients and for monitoring and managing the long-term liver health of recovered patients. As research continues to unfold, it is imperative that the medical community remains vigilant in assessing and addressing the hepatic impacts of COVID-19, ensuring comprehensive care for affected individuals.
reference link : 10.4254/wjh.v16.i1.1
